Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions
- PMID: 3258784
- DOI: 10.1016/0006-8993(88)91603-4
Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions
Abstract
This study examined the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite, 1-methyl-4-phenylpyridine (MPP+) on the levels of dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in push-pull perfusates of the striatum in chloral hydrate-anaesthetized rats. In control animals the levels of DA and DOPAC remained stable for at least 6 h and responded rapidly to a depolarizing stimulus of 25 mM K+. This K+-induced DA release was Ca2+-dependent since no stimulation was observed when the striatal sites were perfused with high K+ in a Ca2+-free medium containing 2 mM EGTA thus verifying that the striatal sites were functionally active. MPTP (0.025 and 0.05 microgram/microliter) stimulated DA release and inhibited DOPAC output in a dose-related manner. MPP+ (0.01, 0.025 and 0.05 microgram/microliter) produced a more robust dose-dependent increase in DA levels in the perfusates; however, the level of suppression of DOPAC was similar to that in response to MPTP. The effect of MPP+ on DA release was attenuated by 10(-6) M benztropine, the DA re-uptake blocker and completely inhibited by 10 micrograms/kg i.p. benztropine and 10(-4) M ouabain, the Na+, K+-ATPase (Na pump) inhibitor. However, although these substances prevented the MPP+-induced release of DA, the levels of DOPAC in the perfusates did not recover and remained completely suppressed suggesting that MPP+ may inhibit extraneuronal rather than intraneuronal monoamine oxidase (MAO). Perfusion of the striatal sites with a Ca2+-free medium containing 2 mM EGTA did not prevent the MPP+-induced DA release indicating that MPP+ does not release DA from the striatal DA terminals by the Ca2+-dependent process of exocytosis. The responses of DA and DOPAC to 25 mM K+ were markedly suppressed in animals treated with MPTP and MPP+, these effects being most severe with the highest dose of MPP+. Moreover, this suppression of the K+-induced responses persisted in animals perfused with MPP+ in the presence of benztropine or ouabain, thus suggesting that MPP+ may have potent deleterious membrane effects. These studies have provided the first direct in vivo demonstration of the action of MPTP and MPP+ and the neuropharmacological basis of this action on DA metabolism in the rat striatum. The results show that the elevated levels of DA in the striatal perfusates are due to a direct action of MPTP and MPP+ on the nigrostriatal DA terminals and cannot be fully accounted for solely by their inhibition of MAO activity and/or inhibition of DA re-uptake.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
The mechanism of action of MPTP and MPP+ on endogenous dopamine release from the rat corpus striatum superfused in vitro.Brain Res. 1986 Mar 12;368(1):134-40. doi: 10.1016/0006-8993(86)91050-4. Brain Res. 1986. PMID: 3485463
-
Effects on dopamine metabolism of MPTP and MPP+ infused through a push-pull cannula into the caudate nucleus of awake adult male rats.Brain Res. 1987 Oct 20;424(1):49-57. doi: 10.1016/0006-8993(87)91191-7. Brain Res. 1987. PMID: 3319041
-
Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites.J Neurochem. 1991 Sep;57(3):981-90. doi: 10.1111/j.1471-4159.1991.tb08247.x. J Neurochem. 1991. PMID: 1677682
-
Dopamine efflux by MPTP and hydroxyl radical generation.J Neural Transm (Vienna). 2002 Sep;109(9):1159-80. doi: 10.1007/s00702-001-0683-2. J Neural Transm (Vienna). 2002. PMID: 12203043 Review.
-
Processing of MPTP by monoamine oxidases: implications for molecular toxicology.J Neural Transm Suppl. 1987;23:73-89. doi: 10.1007/978-3-7091-8901-6_5. J Neural Transm Suppl. 1987. PMID: 3295117 Review.
Cited by
-
Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons.Neurosci Lett. 2016 Jan 26;612:178-184. doi: 10.1016/j.neulet.2015.12.028. Epub 2015 Dec 15. Neurosci Lett. 2016. PMID: 26704434 Free PMC article.
-
Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?Cell Mol Neurobiol. 2001 Jun;21(3):215-35. doi: 10.1023/a:1010991020245. Cell Mol Neurobiol. 2001. PMID: 11569535 Free PMC article. Review.
-
Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure.J Biol Chem. 2015 Mar 13;290(11):6799-809. doi: 10.1074/jbc.M114.631556. Epub 2015 Jan 16. J Biol Chem. 2015. PMID: 25596531 Free PMC article.
-
MPP+-Induced Changes in Cellular Impedance as a Measure for Organic Cation Transporter (SLC22A1-3) Activity and Inhibition.Int J Mol Sci. 2022 Jan 21;23(3):1203. doi: 10.3390/ijms23031203. Int J Mol Sci. 2022. PMID: 35163125 Free PMC article.
-
Human Cortex Spheroid with a Functional Blood Brain Barrier for High-Throughput Neurotoxicity Screening and Disease Modeling.Sci Rep. 2018 May 9;8(1):7413. doi: 10.1038/s41598-018-25603-5. Sci Rep. 2018. PMID: 29743549 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous